Under-representation of women in oncology leadership positions

New initiative aims to promote exchange of ideas among female oncologists and support women with cancer in Greece

2014-09-29

(Press-News.org) A growing number of oncologists in Greece are female, but women continue to be under-represented in leadership positions, according to a survey reported at the ESMO 2014 Congress.

"In Greece, and across Europe, women oncologists still find it hard to access leadership or academic positions," said Dr Helena Linardou, Associate Director of the 1st Department of Oncology at the Metropolitan Hospital, Athens, Greece, who presented the survey results at the congress.

"Women are indeed increasingly choosing oncology specialties in Greece, however, most decision-making posts are still dominated by men across the profession, in private practice, academia and national health environments. This needs to change," she said.

The survey of 80 female members of the Hellenic Societies of Medical, Radiation and Surgical Oncology showed that while women were widely represented in workplaces, team leaders were men in 82% of cases.

"The survey also showed that women oncologists are hugely under-represented in international scientific meetings and scientific society boards, and still have difficulties travelling abroad and accessing education opportunities at international level," Linardou said.

The study was conducted as part of a European initiative of and for female oncology professionals, known as "Women for Oncology" (W4O)[1], launched by the European Society for Medical Oncology in 2013.

The Greek national equivalent, called 'W4O-Hellas', aims to create a support network for female oncologists, but also to provide a platform of direct communication and essential contribution from women doctors to women cancer patients, Linardou explains.

"This forum of women will promote the interaction and exchange of ideas among women oncologists in Greece and across Europe and will embrace and assist them throughout their career in oncology. The novelty, however, is that at the same time, this forum will offer advice, awareness and support directly from women oncologists to women suffering from cancer and their families in Greece."

The group has fund-raising events and public education meetings planned for the immediate future and an inaugural event is scheduled for Sunday, 12 October 2014, in the Athens Concert Hall (Megaron Mousikis).

"We hope to give the opportunity to women professionals from Greece and across Europe to exchange ideas and find common ground, and to discuss openly some issues faced by women with cancer," Linardou said.

"In Europe we are still suffering considerable discrepancies in terms of career opportunities between men and women," said Dr Solange Peters, ESMO Executive Board member, active in the first ESMO W4O Forum in 2013. "Women still have difficulties to access leadership positions, and for them the compatibility between professional career and daily life is still more difficult as compared to male counterparts."

The Greek oncology community should be congratulated to have taken this initiative so seriously, taking into consideration not only women doctors but also creating a link between female practicing oncologists and female cancer patients, Peters added.

"On behalf of the ESMO Women for Oncology initiative, we encourage female colleagues in all European countries to launch similar national projects and support the career of female oncology professionals," she concluded.

INFORMATION:

ELSE PRESS RELEASES FROM THIS DATE:

Is expressive suppression effective in reducing negative emotion?

2014-09-29

A recent study based on a Chinese sample gives an answer to this question. The research shows that in Chinese culture, emotion- expressive suppression is not only able to dampen negative emotion effectively, but also dampen negative emotion faster than Cognitive reappraisal. This sheds much light on how to quickly regulate negative emotion in urgent situations, particularly when people from East-Asian cultures are concerned. This study has been published in SCIENCE CHINA： Life Sciences (IN CHINESE) , which is titled "The efficiency of negative emotion regulation: ...

Using the brain to forecast decisions

2014-09-29

You're waiting at a bus stop, expecting the bus to arrive any time. You watch the road. Nothing yet. A little later you start to pace. More time passes. "Maybe there is some problem", you think. Finally, you give up and raise your arm and hail a taxi. Just as you pull away, you glimpse the bus gliding up. Did you have a choice to wait a bit longer? Or was giving up too soon the inevitable and predictable result of a chain of neural events? In research published on 09/28/2014 in the journal Nature Neuroscience, scientists show that neural recordings can be used to forecast ...

Smart, eco-friendly new battery to solve problems

2014-09-29

Present-day lithium batteries are efficient but involve a range of resource and environmental problems. Using materials from alfalfa (lucerne seed) and pine resin and a clever recycling strategy, Uppsala researchers have now come up with a highly interesting alternative. Their study will be presented soon in the scientific journal ChemSusChem. 'We think our discovery can open several doors to more environment-friendly, energy-efficient solutions for the batteries of the future,' says Daniel Brandell, Associate Professor at the Department of Chemistry, Uppsala University, ...

Protein that causes frontotemporal dementia also implicated in Alzheimer's disease

2014-09-29

SAN FRANCISCO, CA—September 28, 2014—Researchers at the Gladstone Institutes have shown that low levels of the protein progranulin in the brain can increase the formation of amyloid-beta plaques (a hallmark of Alzheimer's disease), cause neuroinflammation, and worsen memory deficits in a mouse model of this condition. Conversely, by using a gene therapy approach to elevate progranulin levels, scientists were able to prevent these abnormalities and block cell death in this model. Progranulin deficiency is known to cause another neurodegenerative disorder, frontotemporal ...

Predicting landslides with light

2014-09-29

WASHINGTON, Sept. 29, 2014—Optical fiber sensors are used around the world to monitor the condition of difficult-to-access segments of infrastructure—such as the underbellies of bridges, the exterior walls of tunnels, the feet of dams, long pipelines and railways in remote rural areas. Now, a team of researchers in Italy are expanding the reach of optical fiber sensors "to the hills" by embedding them in shallow trenches within slopes to detect and monitor both large landslides and slow slope movements. The team will present their research at The Optical Society's (OSA) ...

Scientists identify the signature of aging in the brain

2014-09-29

How the brain ages is still largely an open question – in part because this organ is mostly insulated from direct contact with other systems in the body, including the blood and immune systems. In research that was recently published in Science, Weizmann Institute researchers Prof. Michal Schwartz of the Neurobiology Department and Dr. Ido Amit of Immunology Department found evidence of a unique "signature" that may be the "missing link" between cognitive decline and aging. The scientists believe that this discovery may lead, in the future, to treatments that can slow or ...

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

2014-09-29

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1] in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. "Previously-treated advanced melanoma patients have limited options," says the study's principal investigator, Professor Jeffrey Weber, Director of the Donald A. Adam Comprehensive Melanoma Research Center of Excellence at the Moffitt Cancer Centre, Tampa, Florida. Nivolumab is an antibody ...

New data on combination treatments for melanoma

2014-09-29

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. "Before the results of this study, we knew that cobimetinib plus vemurafenib could be safely delivered together with highly promising rates of tumour shrinkage; however until the performance of a scientifically rigorous randomised trial the potential magnitude of this benefit ...

Studies report new findings on treatment options for mesothelioma

2014-09-29

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid. "Mesothelioma remains a difficult disease to find better treatment options for, so we asked whether high-dose hemithoracic radiotherapy would decrease the rate or delay the time of local recurrence after chemotherapy and radical surgery," says lead author Prof Rolf A. Stahel, from the ...

Promising results shown with targeted approaches in subsets of non-small cell lung cancer

2014-09-29

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain. "Reports of lung cancers bearing mutations in BRAF have generated considerable interest because these mutations may be associated with increased sensitivity to BRAF tyrosine-kinase inhibiting agents," says lead author Dr David Planchard, pulmonary oncologist at the Gustav-Roussy Cancer Campus, Paris, France. ...

LAST 30 PRESS RELEASES:

Study published in NEJM Catalyst finds patients cared for by MedStar Health’s Safe Babies Safe Moms program have better outcomes in pregnancy, delivery, and postpartum

New West Health-Gallup survey finds incoming Trump administration faces high public skepticism over plans to lower healthcare costs

THE LANCET DIABETES & ENDOCRINOLOGY: Global Commission proposes major overhaul of obesity diagnosis, going beyond BMI to define when obesity is a disease.